ALLIANCE PHARMACEUTICAL CORP
10-Q, EX-27, 2000-11-06
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: ALLIANCE PHARMACEUTICAL CORP, 10-Q, 2000-11-06
Next: LNB BANCORP INC, 8-A12G, 2000-11-06



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONDENSED CONSOLIDATED BALANCE SHEETS AND THE CONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>
<CURRENCY> U.S. DOLLARS

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          JUN-30-2001
<PERIOD-START>                             JUL-01-2000
<PERIOD-END>                               SEP-30-2000
<EXCHANGE-RATE>                                      1
<CASH>                                      27,015,000
<SECURITIES>                                   822,000
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                            32,217,000
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                              71,817,000
<CURRENT-LIABILITIES>                       21,996,000
<BONDS>                                              0
                                0
                                      5,000
<COMMON>                                       480,000
<OTHER-SE>                                  21,710,000
<TOTAL-LIABILITY-AND-EQUITY>                71,817,000
<SALES>                                              0
<TOTAL-REVENUES>                                14,000
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                            16,285,000
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             718,000
<INCOME-PRETAX>                           (13,840,000)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                       (13,840,000)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                              (13,840,000)
<EPS-BASIC>                                     (0.29)
<EPS-DILUTED>                                   (0.29)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission